National Cardiogenic Shock Initiative: 1 Year Later
Video Chapters:The Impact of The Cardiogenic Shock Initiative (NCSI):...
October 1, 2018
Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care
Reference: J Am Coll Cardiol 2...
November 29, 2018
The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial
Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses...
November 11, 2018
Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device
Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...
September 18, 2018
Detroit Cardiogenic Shock Initiative: Initial Results
March 21, 2017
Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock
February 16, 2017
How to Best Identify Cardiogenic Shock Patients
May 19, 2016
How to Better Evaluate, Identify and Manage Shock Patients
Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardio...
April 12, 2016
The FDA’s Shock Indication for the Impella
The FDA recently granted Abiomed approval to expand Impella™ 2.5 PMA to treat patients suffering cardiogenic shock follo...
April 11, 2016
Significance of FDA Approval of Impella for Cardiogenic Shock
Listen to Dr. William W. O’Neill, Medical Director for the Center for Structural Heart Disease at Henry Ford Hospital, discus...
April 7, 2016
